MTOR and myeloproliferative disorder: To exploit whether the proliferation of primary MPN cells could be similarly affected by mTOR inhibitors, we incubated CD34+ cells from PMF patients and healthy controls (n = 6 and n = 5, respectively) with increasing concentration of RAD001 and PP242, and measured the proportion of viable cells relative to control wells containing vehicle only; an optimized cytokine cocktail was added to both patients’ and controls’ wells to allow cell survival.